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Introduction. Diabetic neuropathy (DN) is one of the most devastating complications of 
diabetes mellitus; however, in contrast to other countries, there are no scientific studies in Portugal 
evaluating the impact of demographic and clinical characteristics of this pathological entity. The aim 
of this study was to evaluate the impact of gender, metabolic control, age of diabetic patients, as well 
as time of disease progression, the appearance of complaints related to neuropathic pain. 
Material and methods. A multicentre study with a non-probabilistic, convenience sample of 
359 patients was performed employing the quantitative method, using the Statistical Package for 
Social Science 24 software. The p-value of p < 0.05 was defined to consider a result statistically 
significant. The Spearman correlation coefficient (r) was determined to determine the relationship 
between categorical variables. 
Results. There was no statistically significant difference in the prevalence of DN between 
genders (p = 0.633 and r = 0.025). There was a statistically significant relationship between the value 
of HbA1c and DN, with p = 0.010 and r = 0.136. There is a relationship between age and complaints 
of neuropathic pain, with p = 0.034 and r = 0.112. The variable, time of disease progression, is also 
correlated with the appearance of complaints of neuropathic pain with p = 0.020 and r = 0.112. 
Conclusion. The prevalence of neuropathic pain in subjects with diabetes is not negligible 
and is associated with modifiable risk factors that can be identified, possibly modified and prevented. 
The correct approach for these patients, which involves screening and early treatment, is decisive 
improving functionality and quality of life. 
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INTRODUCTION 
Diabetic neuropathy (DN) is the most prevalent 
microvascular complication of diabetes mellitus 
(DM). It is a heterogeneous group of entities that 
can affect different parts of the nervous system, 
with symmetric distal polyneuropathy and diabetic 
autonomic neuropathy being the most common [1]. 
Distal symmetric neuropathy is defined as the 
presence of symptoms or signs of peripheral nerve 
dysfunction in people with diabetes after excluding 
other causes [2]. The most common nerve injury is 
the bilateral and symmetrical lesion of the nerves 
of the lower limbs. This dysfunction mainly affects 
the sensory nerves and the symptoms may vary 
depending on the type of fibres involved. It is a 
devastating complication of DM which can lead to 
foot ulcers, Charcot foot or even amputation [2, 3].  
Neuropathic symptoms can be positive/painful 
or negative/non-painful. Positive symptoms include 
burning sensation, stabbing, electric shocks, constriction 
and allodynia; negative symptoms include itching, 
tingling, numbness or stinging. In this context, 
painful diabetic neuropathy (PDN) has a prevalence 
of around 25–30%. Approximately 80% of PDN 
patients complain of moderate to severe pain. 
Concomitantly, negative symptoms prevail in DN. 
Patients with negative symptoms are at increased 
risk of foot ulcers due to loss of protective 
sensitivity [4, 5, 6]. 
DN affects approximately 50% of the elderly 
with diabetes or with the disease evolving over a 
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long period of time, defined in the literature as a 
progression of over 15–20 years. DN is present at 
the time of diagnosis in about 10% of individuals 
with type 2 diabetes mellitus (DM2), generally 
appearing 5 to 10 years after diagnosis of type 1 
diabetes 1 [1, 3]. 
Approximately 50% of DN cases may be 
asymptomatic and these individuals are at risk of 
foot injuries, since only about 80% of amputations 
are preceded by an ulcer [1, 6]. 
In approaching DN, the following risk factors 
should be taken into account: level and duration of 
hyperglycaemia, age, height, male gender, hypertension, 
smoking and dyslipidaemia. Non-diabetic causes 
of symptomatic polyneuropathy should also be 
taken into account, among which the following 
stand out: metabolic causes (e.g., hypothyroidism, 
porphyria), toxic causes (e.g., alcohol), vitamin B 
deficiency, infection (e.g., acquired immunodeficiency 
virus, leprosy), malignancy (e.g., paraneoplastic 
syndrome), iatrogenic causes (e.g., isoniazid, vincristine 
alkaloids, post-chemotherapy), non-pharmacological 
iatrogenic causes (e.g., post-surgery) and genetic 
causes (e.g., familial amyloidosis). All of these 
variables make DN a first diagnosis of exclusion, 
based on clinical history and objective examination 
[7, 8, 9]. 
Neuropathic pain is caused by a primary 
dysfunction of the nervous system, which may 
have several etiologies [10, 11] and cause about 
5% of neuropathic syndromes in subjects with 
diabetes that are due to other etiologies than 
diabetes [12,13].  
Early detection of DN as well as its correct 
approach is important for several reasons related to 
the fact that there are a number of treatment options. 
It provides the possibility of an early approach to 
the increased risk of foot ulceration, which these 
patients face, since sensorimotor neuropathy and 
peripheral sympathetic neuropathy are the major 
risk factors for foot ulceration [14, 15]. 
Early recognition and appropriate treatment of 
neuropathy in patients with diabetes are important 
for a number of reasons. (DN) is a diagnosis of 
exclusion, since non-diabetic neuropathies may be 
present in patients with diabetes and can be treated 
by specific measures [16]. 
MATERIAL AND METHODS 
This study was approved by all directors off 
all heath units. The aim of this study is to evaluate 
the prevalence of neuropathic pain diagnosis in 
subjects with diabetes followed by Portuguese 
Health Care System and to investigate correlations 
between this diagnosis and the demographic and 
clinical characteristics of diabetics. 
The following questions were posed in order 
to perform the research:  
 Question 1: Does sex condition the onset 
of complaints of neuropathic pain? 
 Question 2: Is the value of glycated 
haemoglobin (HbA1c) related to complaints 
of neuropathic pain? 
 Question 3: Is the diabetic’s age related to 
complaints of neuropathic pain? 
 Question 4: Does the time of disease 
progression affect the appearance of 
complaints of neuropathic pain? 
In order to track and evaluate the prevalence 
of neuropathic pain, the Douleur Neuropathique 4 
(DN4) questionnaire, translated and validated 
for the Portuguese population, was applied because 
it is one of the simplest and briefest, favouring 
its practical applicability in the research context 
in this area, in the context of a consultation 
[24]. A neuropathic pain compatible screening is 
admissible when at least 4 positive-response lines 
are present [24].  
The dependent variable was defined by the 
existence of neuropathic pain in subjects with diabetes 
and the independent variables were defined as age, 
sex, HbA1c level and time of disease progression. 
We attempted to operationalize the variables as 
quantitative, so that: [1] sex would define the 
number of subjects with diabetes who were female 
or male; [2] age would define the number of 
subjects with diabetes aged 65 years or older or 
under 65 years, since the age over 64 years is the 
most consensual to define the elderly; [3] the 
HbA1c level would define the number of subjects 
with diabetes with HbA1c greater than or equal to 
7.0% or less than 7.0%; [4] the time of disease 
progression would define the number of subjects 
with diabetes who had the disease for less than 10 
years since diagnosis of diabetes, or 10 or more 
years since diagnosis of the disease. 
The study population consisted of patients 
enrolled in the patient lists of the researchers 
involved in this project. They belong to several 
primary health care units (PHC) in Portugal, as 
well as the diabetes consultation of a national 
hospital. The sample was represented by 60% 
subjects with diabetes belonging to the population 
mentioned above, corresponding to 359 patients 
who were part of this research design (306 patients 




followed in PHC and 53 in the hospital visit). This 
is a multicentre study, with a non-probabilistic, 
convenience sample. This type of sampling is very 
common in research and consists of selecting a 
sample of the population that is accessible. Thus, 
the patients included in this study were not selected 
by randomization, but rather because they stated 
they were willing to participate.  
Patients who presented any of the following 
pathologies or clinical conditions when the questionnaire 
was applied were excluded: sequelae of cerebrovascular 
accident, spinal cord injury, multiple sclerosis, 
radiculopathies, nerve damage, traumatic or 
postoperative injuries. Patients who were taking 
the following medication were also excluded: 
amitriptyline, carbamazepine, duloxetine, gabapentin, 
imipramine, lidocaine plaster, nortriptyline, pregabalin, 
tramadol, tapentadol or venlafaxine. 
The quantitative method was employed with 
the Statistical Package for Social Sciences 24 
(SPSS) being used for the statistical treatment of 
data, with the aim of contributing to the development 
and validation of knowledge, thus offering the 
possibility of generalizing the results, as well as 
predicting them. The p value defined for statistical 
significance result was p < 0.05. Later, the qualitative 
method was also used to analyse and interpret the 
results. To determine the relationship between 
categorical variables, the Spearman correlation 
coefficient (r) was determined. 
RESULTS 
359 questionnaires were applied, of which 
DN4 was an integral part. In a first analysis, 
89.14% of the diabetic patients consulted did not 
meet criteria for the diagnosis of neuropathic pain, 
since they did not present a score on the DN4 of at 
least 4 points. The remainder 10.86% met the 
positive criteria for neuropathic pain.  
Description of the sample: as shown in 
Table 1, we found that 54.87% of the subjects with 
diabetes are male and 45.13% are female. It was 
possible to verify that 30.08% of subjects with 
diabetes are less than 65 years old, with 69.92% 
being 65 years of age or older. We also observed 
that 60.73% of diabetic patients had been 
diagnosed with the disease less than 10 years prior 
to the study and 39.27% of subjects with diabetes 
had 10 or more years of disease progression since 
the diagnosis of the disease. Finally, when the 
questionnaires were applied, 62.40% of the 
subjects with diabetes were found to have an 
HbA1c value of less than 7.0% and, 37.60% of the 
subjects with diabetes had an HbA1c greater than 
or equal to 7.0%.  
 
Table 1 
Description of sample 
CHARACTERIZATION OF SAMPLE NO. OF PATIENTS PERCENTAGE OF PATIENTS 
DN4 ≥ 4   39 10.86% 
DN < 4 320 89.14% 
MALES 197 54.87% 
FEMALES 162 45.13% 
< 65 YEARS 108 30.08% 
≥ 65 YEARS 251 69.92% 
DIAGNOSIS < 10 YEARS 218 60.73% 
DIAGNOSIS ≥ 10 YEARS 141 39.27% 
HBA1C < 7.0% 224 62.40% 
HBA1C ≥ 7.0% 135 37.60% 
 
At the physical examination, we verified that 
7.80% of subjects with diabetes have hypoesthesia 
at the sting in the region where the pain is located 
and 7.52% have hypoesthesia by touching and, 
also in the painful area. We also observed that in 
4.18% of subjects with diabetes, the pain is caused 
by mild friction. 
The symptom mentioned most often by the 
patients was numbness, present in 21.72% of 
subjects with diabetes, followed by paraesthesia 
and stinging, with 16.71% and 15.56% respectively. 
These data can be observed in more detail in 
Table 2. 
Statistical inference: We intended to study 
whether there was a relationship between the female 
or male sex and the emergence of complaints of 
neuropathic pain. It was found that 48.7% of the 
patients with neuropathic pain were women (11.7% 
of the total women) and the remaining 51.3% were 
men (10.2% of all men). There was no statistically 
significant difference between the sexes (p = 0.633, 
r = 0.025). 
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Table 2 
Description of the symptoms according to the DN4 questionnaire 
SYMPTOMS NO. OF PATIENTS PERCENTAGE OF PATIENTS 
BURNING 31 8.64% 
FEELING OF PAINFUL COLD 17 4.74% 
ELECTRIC SHOCK 19 5.29% 
PARAESTHESIA 60 16.71% 
STINGING  56 15.56% 
NUMBNESS 78 21.72% 
ITCHING 48 13.37% 
HYPOAESTHESIA TO THE TOUCH 27 7.52% 
HYPOESTHESIA TO THE STING 28 7.80% 
PAIN CAUSED BY LIGHT FRICTION 15 4.18% 
TOTAL PATIENTS 
The same subject with diabetes may refer more than one symptom.  
These results regard the application of the ND4 questionnaire  
to the studied sample, consisting of 359 patients. 
 
On the other hand, neuropathic pain was 
observed to be was significantly more prevalent in 
individuals with HbA1c greater than or equal to 
7% than in those with lower values (16.3% vs. 
7.6%, p = 0.010, r = 0.136). Of the total number of 
patients with neuropathic pain (n = 39), 56.4% had 
HbA1C greater than or equal to 7%. The HbA1c 
value seems to be related to complaints of neuropathic 
pain. 
Regarding the relationship between the age of 
subjects with diabetes and complaints of neuropathic 
pain, it was found that these were significantly more 
prevalent in individuals aged 65 years or older (13.1%) 
than in individuals under 65 (5.6%), with p = 0.034 and 
r = 0.112. In fact, of the total number of patients with 
neuropathic pain, 84.6% was 65 years or older. 
Finally, there was a higher prevalence of 
neuropathic pain in patients with 10 or more years 
of disease progression compared to those with a 
duration of less than 10 years (15.6% vs 7.8%, 
p = 0.020, r = 0.112). Of the total number of 
patients with neuropathic pain, 56.4% had had the 
disease for 10 years or more. 
We realised that 38.1% of men and 40.7% of 
women had been diagnosed with diabetes 10 or 
more years ago, and there was no statistically 
significant relationship between sex and the 
disease duration (r = 0.027 and p = 0.606). There 
was also no statistically significant relationship 
between sex and HbA1c values, with 37.1% for 
men and 38.3% for women with HbA1C values 
equal or greater to 7% (r = 0.012, p = 0.813). 
 
Table 3 
Statistical inference applied to the study variables 
Variable: sex Variable: HbA1c Variable: age Variable: disease progression 
  
man woman ≥ 7% < 7% ≥ 65 < 65 ≥ 10 < 10 
% with neuropathic 
pain (n = 39) 
51.3% 
(n = 20/39) 
48.7% 








(n = 6/39) 
56.4% 
(n = 22/39) 
43.6% 
(n = 17/39)
Total proportion of 
patients  
10.2% 
(n = 20/197) 
11.7% 








(n = 6/108) 
15.6% 
(n = 22/141) 
7.8% 
(n = 17/218)
p-value 0.633 0.010 0.034 0.020 
Spearman 
correlation (r) 0.025 0.136 0.112 0.112 
 
DISCUSSION 
This research demonstrates the importance 
of early diagnosis of DN, but above all, it aims to 
raise awareness of the need to incorporate DN 
screening and assessment methods in order to act 
upon their natural history and thus gain health gains.  
In the more recent literature, males are defined 
as a risk factor for the development of DN, and 
there are some documented statistical correlations, 
such as the fact that stature also conditions DN, in 
the sense that taller subjects with diabetes have a 
higher prevalence of DN. Their percentiles of taller 
stature may, in part, justify the fact that males are at 
higher risk of developing ND [7, 9]. On the other 
hand, previous studies have shown that there is a 
relationship between male and DN, directed at 
complaints of sexual dysfunction, a variable that is 




not addressed in the data collection instrument. 
The authors of this study chose to evaluate 
whether there is a statistical relationship between 
females and DN. This was not found, so the null 
hypothesis prevails, that is, the female sex does 
not condition the appearance of DN. It should be 
noted that the statistical data presented do not 
allow us to discern the relation between male sex 
and DN as a conditioning factor, despite the fact 
that their relationship is already established, but 
taking variables such as sexual dysfunction or 
height into account.  
As mentioned in this investigation, the symptom 
numbness was the one most mentioned by subjects 
with diabetes, when filling the DN4 questionnaire, 
with 21.72%, followed by the paraesthesia and 
stinging, with 16.71% and 15.56% respectively. 
The design of the investigation does not allow us 
to infer about the correlation of these symptoms 
and the diagnosis of DN, if these symptoms 
precede diagnosis, if they function as a marker of 
risk or if they are highlighted because patients 
better perceive the symptoms. It would, however, 
be interesting to ascertain these relationships in 
future studies.   
Recent studies have shown a high prevalence 
of altered oral glucose tolerance in patients with 
peripheral sensory neuropathy [16, 17], which is 
consistent with the fact that the relationship between 
HbA1c equal to or greater than 7% and DN is 
statistically significant. It is consensual that the 
increase of glycaemia leads to the increase of its 
degradation products, such as sorbitol, leading to 
an increase in oxidative stress and to the flow of 
sodium and water to nerve cells, compromising 
their normal activity. This alteration in oral glucose 
tolerance may be responsible for the decrease in 
the density of intraepidermal nerve fibres in diabetic 
neuropathic pain [18, 19]. 
DN affects about 50% of people with long-
term diabetes, specifically subjects with diabetes 
with more than 15 years of disease progression. 
On the other hand, we know that DN is present at 
the time of the diagnosis of DM2 in about 10% of 
people with diabetes [20, 21]. These data, taken as 
a whole, may help to characterize the statistical 
significance between the variables “age greater 
than or equal to 65 years” and “more than 10 years 
of DM2 progression” with the appearance of DN. 
A long progression of the disease, defined 
in this study as over 10 years, when associated 
with an absence of adequate metabolic control, 
leads to the accumulation of homocysteine and 
sorbitol, with a consequent decrease in nitric 
oxide levels, causing endothelial and nerve cell 
lesions [22, 23]. We also know that studies in this 
area document the decrease in the density of 
intraepidermal nerve fibres in painful neuropathy, 
explained by the decrease in the physiological 
response to algic modulators, such as serotonin but, 
above all, prostaglandins. This corroborates the 
results obtained in this investigation at the 
pathophysiological level, since a statistically 
significant relationship between the length of 
disease progression of DM2 and DN was observed. 
It was found that 84.6% of patients with 
neuropathic pain were 65 years of age or older, 
which testifies to the synergy of the variables age 
and length of disease progression, that is, older 
patients are also those who accumulate higher 
metabolic disease burden and which consequently 
translates into symptoms.  
As mentioned previously, in the physical 
examination of subjects with diabetes, we observed 
that 7.8% of these had hyposthesia to the sting in 
the region where the pain is located and, 7.52% 
have hyposthesia to the touch, also in the painful 
region, results that are consistent with sensitive 
peripheral neuropathy due to poor metabolic control 
leading to intra-epidermal nerve fiber dysfunction, 
nerve cell death, and resistance to painkillers such 
as serotonin and prostaglandins. 
Rigorous metabolic control is crucial from 
the initial phase of DM, since only then can it be 
possible to modify the progression of the disease, 
and to avoid the nerve lesions observed in patients, 
either with inadequate metabolic control, or with a 
disease progression over 10 years. 
CONCLUSION 
This study is the first in Portugal to address 
the problem of DN, a degenerative and debilitating 
disease, with an impact on patients’ quality of life. 
It is a pathology that is poorly diagnosed and treated, 
and its approach must be initiated in PHC and be 
transversal to the specialities involved in diabetic 
foot consultation.  
When a patient with a clinical context suggestive 
of DN is approached, careful and systematized 
anamnesis is essential in order to investigate symptoms 
consistent with other causes of pain or neuropathy. 
It is important to address the risk factors of DN, 
with special attention to the variables studied: level 
of HbA1c, duration of hyperglycaemia and age. 
Other risk factors are equally important, such as 
height, male gender, hypertension, smoking, and 
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dyslipidaemia. Thus, treatment and clinical approach 
should address not only the patient’s metabolic 
control, but also the correction of modifiable risk 
factors. 
Other lines of research are pertinent, such as 
studying the relationship between vitamin B complex 
levels and the emergence of DN. We know that 
DM can be considered a thiamine-deficient state 
due to the accelerated metabolism of glucose in non-
insulin dependent tissues, such as the vessel wall. 
Moreover, pyridoxine, essential for the synthesis 
of neurotransmitters, reduction of pain intensity 
and dormancy, and cyanocobalamin, which promotes 
myelin sheath regeneration and relief of paraesthesia, 
are decreased in patients with DM. These phenomena 
appear not only in the biochemical context of the 
diabetic, with increased levels of homocysteine 
and methylmalonic acid, which in turn increase 
resistance to these vitamins, but also by the action 
of metformin, due to its effects on intestinal 
dynamics. 
This research also intends to convey the 
importance of addressing DN in diabetes surveillance 
consultations, since it has been shown that the 
prevalence of neuropathic pain in patients with 
diabetes is not negligible, suggesting the particular 
relevance of conducting the DN4 questionnaire to 
screen for neuropathic pain. This is especially important 
in patients aged 65 or over, 10 or more years of 
disease progression and HbA1C values greater than 
or equal to 7%, because if DN goes undiagnosed, it 
is not possible to apply its treatment, aimed at 
improving quality of life, physical and emotional 
function, as well as pain relief. The importance of 
an early diagnosis makes pharmacological treatment 
possible, which must also be started early. 
 
 
Introducere. Neuropatia diabetică (DN) este una dintre cele mai devastatoare 
complicații ale diabetului zaharat, În Portugalia nu sunt încă studii care să evalueze 
impactul său demografic și caracteristicile sale clinice. Scopul acestui studiu a fost 
de a evalua impactul genului, al controlului metabolic, al vârstei, precum și al 
progresului bolii asupra durerii neuropate. 
Materiale și metode. A fost realizat un studiu multicentric cu o populație de 
359 de pacienți la care s-a folosit softul SPSS versiunea 24. Valorea lui p sub 0,05 
a fost considerată relevantă statistic. Coeficientul Speraman a fost folosit pentru a 
corela variabilele. 
Rezultate. Nu a existat nicio diferență semnificativă statistic între prevalențele 
DN la ambele sexe (p = 0,633 și r = 0,025). A fost stabilită o asociere semnificativă 
statistic între valoarea HbA1c și DN (r = 0,136 cu p = 0,01). S-a găsit o corelație 
pozitivă între vârstă și durerea neuropată (r = 0,112, p = 0,034). Progresia bolii  
a fost și ea corelată cu apariția manifestărilor durerii neuropate (p = 0,02 și 
r = 0,112).  
Concluzii. Prevalența DN nu este neglijabilă în cadrul populației cu diabet 
zaharat și este asociată cu factori de risc modificabili ce pot fi preveniți și identificați. 
Pentru îmbunătățirea calității vieții sunt imperios necesare screening-ul și tratamentul 
cât mai precoce.  
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